Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus.

Abstract

PURPOSE:

Following surgery for nonmetastatic renal cell carcinoma with tumor thrombus the risk of recurrence is significant but variable among patients. The purpose of this study was to develop and validate a predictive nomogram for individual estimation of recurrence risk following surgery for renal cell carcinoma with venous tumor thrombus.

MATERIALS AND METHODS:

Comprehensive data were collected on patients with nonmetastatic renal cell carcinoma and thrombus treated at a total of 5 institutions from 2000 to 2013. Independent predictors of recurrent renal cell carcinoma from a competing risks analysis were developed into a nomogram. Predictive accuracy was compared between the development and validation cohorts, and between the nomogram and the UISS (UCLA Integrated Staging System, SSIGN (Stage, Size, Grade and Necrosis) and Sorbellini models.

RESULTS:

A total of 636 patients were analyzed, including the development cohort of 465 and the validation cohort of 171. Independent predictors, including tumor diameter, body mass index, preoperative hemoglobin less than the lower limit of normal, thrombus level, perinephric fat invasion and nonclear cell histology, were developed into a nomogram. Estimated 5-year recurrence-free survival was 49% overall. Five-year recurrence-free survival in patients with 0, 1, 2 and more than 2 risk factors was 77%, 53%, 47% and 20%, respectively. Predictive accuracy was similar in the development and validation cohorts (AUC 0.726 and 0.724, respectively). Predictive accuracy of the thrombus nomogram was higher than that of the UISS (AUC 0.726 vs 0.595, p = 0.001), SSIGN (AUC 0.713 vs 0.612, p = 0.04) and Sorbellini models (AUC 0.709 vs 0.638, p = 0.02).

CONCLUSIONS:

We present a predictive nomogram for postoperative recurrence in patients with nonmetastatic renal cell carcinoma with venous thrombus. Improving individual postoperative risk assessment may allow for better design and analysis of future adjuvant clinical trials.

• Authors: E Jason Abel, Timothy A Masterson, Jose A Karam, Viraj A Master, Vitaly Margulis, Ryan Hutchinson, C Adam Lorentz, Evan Bloom, Tyler M Bauman, Christopher G Wood, Michael L Blute Jr
• Journal: The Journal of urology (J Urol) Vol. 198 Issue 4 Pg. 810-816 (10 2017) ISSN: 1527-3792 [Electronic] United States
• PMID: 28411071 (Publication Type: Journal Article, Multicenter Study, Validation Study)
• Copyright: Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Topics

• Aged
• Carcinoma, Renal Cell (mortality, pathology, surgery)
• Disease-Free Survival
• Female
• Humans
• Kidney Neoplasms (mortality, pathology, surgery)
• Male
• Middle Aged
• Neoplasm Invasiveness (pathology)
• Neoplasm Recurrence, Local (diagnosis, prevention & control)
• Neoplasm Staging
• Nephrectomy
• Nomograms
• Predictive Value of Tests
• Renal Veins (pathology, surgery)
• Risk Assessment (methods)
• Venous Thrombosis (pathology, surgery)